Menu

Two Performance Studies on Idylla™ MSI Biomarkers Selected for Publication at ASCO Conference

Non-regulated information

Biocartis Abstract on Performance Idylla™ ctRAS Liquid Biopsy Tests Selected for Oral Presentation at 2018 American Association for Cancer Research Meeting

Non-regulated information

Biocartis Establishes R&D Center in the US

Biocartis team strengthened with joining of the Janssen Idylla™ assay development team
Non-regulated information

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla™ platform

Non-regulated information

Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound

Non-regulated information

Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla™ RAS Biomarker Tests

Agreement aims to deliver faster biomarker results to realize more informed treatment decisions
Non-regulated information

Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany

The Idylla™ ctRAS liquid biopsy tests detect RAS mutations in patients with metastatic colorectal cancer
Non-regulated information

Idylla™ Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference

Non-regulated information

Idylla™ Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

First test cleared for use on the Idylla™ platform by US FDA
Non-regulated information

Strong performance data of proprietary MSI Biomarkers for the Idylla™ MSI Test to be published at ESMO

Non-regulated information